Abstract
Synopsis
Porcine-derived lung surfactant (PLS; Curosur®) has shown efficacy in neonatal respiratory distress syndrome. PLS consists of phospholipids, mainly dipalmitoylphosphatidylcholine, the primary surface-active agent of natural lung surfactant, and pulmonary surfactant-associated proteins which facilitate spreading and adsorption of the surface-active agent at the air-alveolar interface.
Intratracheal administration of a single dose of PLS 200 mg/kg significantly improves the survival rate and reduces the incidence of bronchopulmonary dysplasia at 28 days in premature infants (birthweight 700 to 2000g) with severe respiratory distress syndrome (fraction of inspired oxygen ≥ 0.60). PLS also reduces the incidence of air leak events such as pulmonary interstitial emphysema and pneumothorax. The response rate may be further improved by administration of additional 100 mg/kg doses at 12-hour intervals to infants showing a poor response or relapse after a single dose. PLS prophylaxis reduces the incidence and severity of respiratory distress syndrome in premature infants at high risk of developing the disease; however, it remains unclear whether the eventual clinical outcome is similar or superior to that observed in infants who receive rescue treatment.
PLS is well tolerated and does not appear to increase the incidence of complications of prematurity or respiratory distress syndrome, including patent ductus arteriosus and intraventricular haemorrhage. Although its effect on long term development requires further investigation, early indications are that PLS is not associated with any long term adverse sequelae.
Comparative trials are clearly warranted to determine the efficacy and toler-ability of PLS relative to that of other available surfactant preparations, particularly to explore preliminary indications that a more rapid effect of natural surfactants such as PLS (compared with synthetic products) may correlate with improved clinical outcomes, and that PLS may result in fewer complications than synthetic preparations.
Thus, available data show PLS to be a very effective agent for the treatment and prophylaxis of neonatal respiratory distress syndrome, and that it may have some advantages over synthetic preparations.
Neonatal Respiratory Distress Syndrome and Exogenous Surfactant Replacement Therapy
Endogenous lung surfactant lowers surface tension forces at the air-alveolar in-terface, thereby preventing the alveoli from collapsing during expiration. Its deficiency in premature infants due to lung immaturity at birth can lead to the development of neonatal respiratory distress syndrome. This disease affects about 60 to 70% of infants born at less than 30 weeks’ gestation and is associated with high morbidity and increased mortality. The risk of developing respiratory distress syndrome is increased by premature birth, male sex, delivery by caesarean section, being a second-born twin, familial history and maternal diabetes mellitus.
Treatment consists of supplementary oxygen and mechanical ventilation to facilitate gas exchange, and replacement therapy with exogenous lung surfactant. Lung surfactant consists of phospholipids, which are the primary surface-active agents, and pulmonary surfactant-associated proteins, which facilitate adsorption, spreading and recycling of the surfactant within the lungs.
Administration of artificial or natural exogenous surfactant preparations reduces the ventilatory requirement (which can cause complications such as pneumothorax and pulmonary interstitial emphysema) and significantly improves the clinical outcome in the majority of premature infants with respiratory distress syndrome. However, approximately 10 to 25% of infants show a poor response to surfactant replacement therapy, which may be due to lung immaturity, protein leakage across the alveolar-capillary membrane, disease severity, inadequate dosage, uneven distribution or insufficient levels of surfactant, perinatal asphyxia, patent ductus arteriosus or the presence of congenital infection. Whether there is an increased risk of infection and/or immunological sensitisation to foreign proteins and phospholipids found in exogenous surfactant preparations in infants remains unclear.
Pharmacological Properties of Porcine-Derived Lung Surfactant
Porcine-derived lung surfactant (PLS; CurosurfaR consists of approximately 99% polar lipids (mainly phospholipids) and 1% hydrophobic, low molecular weight proteins (surfactant-associated proteins B and C). The drug significantly improved lung expansion and gas exchange in preterm rabbit pups to a level similar to that seen in near-term ventilated pups and appeared more effective than various artificial surfactant preparations in this regard. PLS has also shown efficacy in adult guinea-pigs with severe respiratory insufficiency induced by lung lavage and in a rabbit model of meconium aspiration.
Inhibition of the surface properties of PLS by plasma proteins (fibrinogen > haemoglobin > albumin) has been demonstrated in vitro at protein: surfactant concentration ratios of >1: 1.
Clinical Efficacy
PLS administered as rescue therapy significantly improved clinical outcome in premature infants with severe respiratory distress syndrome [birthweight 700 to 2000g; fraction of inspired oxygen (FiO2) >- 0.60] in randomised multicentre trials. Compared with untreated controls, intratracheal administration of a single bolus of PLS 200 mg/kg 2 to 15 hours after birth caused significant improvements in gas exchange and oxygenation, which were evident within 5 minutes of drug administration.
The 28-day mortality rate was significantly lower in PLS recipients versus untreated controls (31 vs 51%), the incidence of bronchopulmonary dysplasia in survivors was reduced by about 57% (23 vs 53%), and there was an increase in the combined incidence of survival without bronchopulmonary dysplasia compared with untreated controls (55 vs 26%). Administration of additional 100 mg/kg doses at 12-hour intervals to infants still requiring high supplemental oxygen after the first dose further reduced the 28-day mortality rate with or without bronchopulmonary dysplasia. Furthermore, the mortality rate was lower in infants treated at an earlier stage of the disease (Fi02 0.40 to 0.59) compared with late treatment once the disease became severe (FiO2 >- 0.60).
PLS prophylaxis in premature infants (26 to 29 weeks’ gestation) significantly reduced the incidence and severity of respiratory distress syndrome compared with controls (incidence of severe respiratory distress syndrome 19 vs 36%), and reduced the 28-day mortality rate from 19 to 11%. However, the clinical outcome at 28 days did not differ significantly between infants receiving prophylaxis and those eligible for rescue treatment. Findings of a recent meta-analysis suggest that prophylaxis is more beneficial than rescue treatment; thus larger trials comparing the efficacy of these 2 treatment regimens are warranted, as are studies to identify subgroups of infants likely to receive the most benefit from PLS prophylaxis. While preliminary findings suggest that natural surfactants such as PLS may act more rapidly than synthetic surfactants, comparative clinical studies with other surfactant preparations are lacking.
Clinical Tolerability
PLS administration has been well tolerated in multicentre clinical trials (including >2900 patients), in which it did not appear to increase the incidence of complications of prematurity or respiratory distress syndrome in premature infants (700 to 2000g birth weight). Premature infants treated with PLS had a lower incidence of pulmonary air leak events (pulmonary interstitial emphysema and pneumothorax), and the number of infants with patent ductus arteriosus, intraventricular haemorrhage, retinopathy of prematurity, pneumonia, septicaemia or necrotising enterocolitis did not appear to differ significantly between PLS recipients and untreated or historical controls. PLS does not appear to increase the incidence of apnoea of prematurity or pulmonary haemorrhage; however, this requires further study.
Preliminary results at 2-year follow-up indicate that PLS administration at birth does not appear to affect the incidence of functional handicaps or overall growth and development compared with no treatment, and does not appear to adversely affect immunological sensitisation to lung surfactant compared with that observed in untreated controls. However, the longer term tolerability of surfactant replacement therapy as measured by effects on development remains unclear.
Dosage and Administration
PLS 100 or 200 mg/kg administered intratracheally as a single bolus (concentration 80 g/L; total volume 1.25 or 2.5ml) over a few seconds is recommended to treat premature infants with established respiratory distress syndrome (birth-weight 700 to 2000g). Infants still requiring supplemental oxygen 12 hours postdose (Fi02 > 0.40) may be given an additional 100 mg/kg dose, and a further dose (100 mg/kg) may be given 12 hours later if FiO2 remains above 0.40. Infants at high risk of developing respiratory distress syndrome may be treated with a single 100 or 200 mg/kg dose within 10 minutes of birth as prophylaxis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dechant KL, Faulds D. Colfosceril palmitate: a review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosur® Neonatal™) in neonatal respiratory distress syndrome. Drugs 1991; 42: 877–94
Gortner L. Natural surfactant for neonatal respiratory distress syndrome in very premature infants: a 1992 update. J Perinat Med 1992; 20: 409–19
Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861–8
Reynolds MS, Wallander KA. Use of surfactant in the prevention and treatment of neonatal respiratory distress syndrome. Clin Pharm 1989; 8: 559–76
Speer CP, Halliday HL. Surfactant therapy in the newborn. Curr Paediatr 1994; 4: 5–9
Stark AR, Frantz ID. Respiratory distress syndrome. Pediatr Clin North Am 1986; 33: 533–43
Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 96: 517–23
Robertson B. Corticosteroids and surfactant for prevention of neonatal RDS. Ann Med 1993; 25: 285–8
Walti H, Couchard M, Relier JP. Neonatal diagnosis of respiratory distress syndrome. Eur Respir J 1989; 2 Suppl.3: 22S–7S
Van Iwaarden JF. Surfactant and the pulmonary defence system. In: Robertson et al, editors. Pulmonary surrfactant: from molecular biology to clinical practice. Amsterdam: Elsevier Science Publishers, 1992: 215-27
Van Iwaarden JF, Shimizu H, Van Golde PHM, et al. Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J 1992; 286: 5–8
Hallman M, Merritt TA, Bry K. The fate of exogenous surfactant in neonates with respiratory distress syndrome. Clin Pharmacokinet 1994; 26: 215–32
Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1: 55–9
Collaborative European Multicentre Study Group. Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Eur J Pediatr 1991; 150: 433–9
Segerer H, Stevens P, Schadow B, et al. Surfactant substitution in ventilated very low birth weight infants: factors related to response types. Pediatr Res 1991; 30: 591–6
Jobe A. Protein leaks and surfactant dysfunction in the pathogenesis of respiratory distress syndrome. Eur Respir J 1989; 2 Suppl.3: 27s–32s
Seeger W, Grube C, Günther A, et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993; 6: 971–7
Saugstad OD, Halliday HL, Robertson B, et al. Replacement therapy with porcine natural surfactant — current status and future challenges. Biol Neonate 1993; 64: 269–78
Strayer DS. Immunogenicity of pulmonary surfactant preparations. Clin Immunother 1994; 1: 441–8
Strayer DS, Merritt TA, Lwebuga-Mukasa J, et al. Surfactant-anti-surfactant immune complexes in infants with respiratory distress syndrome. Am J Pathol 1986; 122: 353
Strayer DS, Hallman M, Merritt TA. Immunogenicity of surfactant II. Porcine and bovine surfactants. Clin Exp Immunol 1991; 83: 41–6
Chida S, Phelps DS, Soll RF. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991; 88: 84–9
Speer CP, Götze B, Curstedt T, et al. Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf). Pediatr Res 1991; 30: 69–74
Moya FR, Hoffman DR, Zhao B, et al. Platelet-activating factor in surfactant preparations. Lancet 1993; 341: 858–9
Berggren P, Curstedt T, Grossmann G, et al. Physiological activity of pulmonary surfactant with low protein content; effect of enrichment with synthetic phospholipids. Exp Lung Res 1985; 8: 29–51
Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988; 82: 683–91
Noack G, Berggren P, Curstedt T, et al. Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant. Acta Paediatr Scand 1987; 76: 697–705
Robertson B, Curstedt T. Structural and functional characterization of porcine surfactant isolated by liquid-gel chromatography. Prog Respir Res 1990; 25: 237–46
Bevilacqua G, Halliday H, Parmigiani S, et al. Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress. J Perinat Med 1993; 21: 329–40
Robertson B, Curstedt T, Grossmann G, et al. Prolonged ventilation of the premature newborn rabbit after treatment with natural or apoprotein-based artificial surfactant. Eur J Pediatr 1988; 147: 168–73
Kobayashi T, Curstedt T, Grossmann G, et al. Inhibition of exogenous surfactant in ventilated immature newborn rabbits. Respir Physiol 1989; 76: 1–12
Noack G, Curstedt T, Grossmann G, et al. Passive expiratory flow-volume recordings in immature newborn rabbits. Effect of surfactant replacement on the time constant of the respiratory system. Respiration 1990; 57: 1–5
Sun B, Kobayashi T, Curstedt T, et al. Application of a new ventilator-multi-plethysmograph system for testing efficacy of surfactant replacement in newborn rabbits. Eur Respir J 1991; 4: 364–70
Bongrani S, Fornasier M, Papotti M. Lung gas volumes and expiratory time constants in immature newborn rabbits treated with natural or synthetic surfactant or detergents. Biol Neonate 1994; 65: 406–15
Halliday H, Robertson B, Nilsson R, et al. Automated image analysis of alveolar expansion patterns in immature newborn rabbits treated with natural or artificial surfactant. Br J Exp Pathol 1987; 68: 727–32
Berggren P, Lachmann B, Curstedt T, et al. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage. Acta Anaesthesiol Scand 1986; 30: 321–8
Lachmann B, Berggren P, Curstedt T, et al. Surfactant replacement in experimental respiratory distress syndrome induced by lung lavage. Prog Respir Res 1984; 18: 251–6
Sun B, Curstedt T, Song G-W, et al. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate 1993; 63: 96–104
Collaborative European Multicenter Study Group. A2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Eur J Pediatr 1992; 151: 372–6
Halliday HL, Tarnow-Mordi WO, Corcoran JD, et al. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1993; 69: 276–80
Speer CP, Robertson B, Curstedt T, et al. Randomized European multicentre trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992; 89: 13–20
McCord FB, Curstedt T, Halliday HL, et al. Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome. Arch Dis Child 1988; 63: 10–6
Shinwell ES, Zmora E, Leven D, et al. Surfactant replacement therapy for respiratory distress syndrome: a pilot study. In Hebrew. J Israel Med Assoc 1992; 123: 1–4
Speer CP, Harms K, Müller U, et al. Surfactant replacement therapy in preterm infants with respiratory distress syndrome [in German]. Monatsschr Kinderheilkd 1988; 136: 65–70
Valls-i-Soler A, Lizarraga M, de Heredia JL, et al. Effectiveness of Curosurf for severe respiratory distress syndrome: a case-control study. Biol Neonate 1992; 61 Suppl. 1: 21–5
Walti H, Relier JP, Huon C, et al. Treatment of severe hyaline membrane disease with a single dose of natural porcine exogenous surfactant. A randomized trial. Immediate therapeutic effects and outcome at 28 days of life [in French]. Arch Fr Pediatr 1990; 47: 329–34
Northway WH, Rosan RC. Radiographic features of pulmonary oxygen toxicity in the newborn: bronchopulmonary dysplasia. Radiology 1968; 91: 49–58
Speer CP, Gefeller O, Groneck P, et al. Randomized clinical trial of surfactant therapy for neonatal respiratory distress syndrome: comparison of two treatment regimens with natural surfactant preparations. Arch Dis Child. In press
Egberts J, de Winter P, Sedin G, et al. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less the 30 weeks’ gestation: a randomized trial. Pediatrics 1993; 92: 768–74
Egberts J, Walti H, Bevilacqua G, et al. Meta analysis of three prophylaxis versus rescue trials with Curosurf [abstract]. 8th International Workshop on Surfactant Replacement, Oslo May 20-22, 1993
Papile LA, Burstein J, Koffler H. Incidence and evolution of subependymal and intraventricular haemorrhage. A study of infants with birthweight less than 1500gm. J Pediatr 1978; 92: 529–34
Amato M, Hüppi, Markus D. Prevention of symptomatic patent ductus arteriosus with ethamsylate in infants treated with exogenous surfactant. J Perinatol 1993; 13: 2–7
Cowan F, Whitelaw A, Wertheim D, et al. Cerebral blood flow velocity changes after rapid administration of surfactant. Arch Dis Child 1991; 66: 1105–9
van Bel F, de Winter PJ, Wijnands HBG, et al. Cerebral and aortic blood flow velocity patterns in preterm infants receiving prophylactic surfactant treatment. Acta Paediatr Scand 1992; 81: 504–10
Dorrepaal CA, Benders MJNL, Steendijk P, et al. Cerebral hemodynamics and oxygenation in preterm infants after low-vs. high-dose surfactant replacement therapy. Biol Neonate 1993; 64: 193–200
Edwards AD, McCormick DC, Roth SC, et al. Cerebral hemodynamic effects of treatment with modified natural surfactant investigated by near infrared spectroscopy. Pediatr Res 1992; 32: 532–6
Rankin SJA, Tubman TRJ, Halliday HL, et al. Retinopathy of prematurity in surfactant treated infants. Br J Ophthalmol 1992; 76: 202–4
Walti H, Boulé M, Moriette G, et al. Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth. Biol Neonate 1992; 61 Suppl. 1: 48–53
Kristensen J, Wojnar-Horton R. Pulmonary surfactant therapy: costs versus benefits. Aust J Hosp Pharm 1994; 24: 114
Phibbs CS, Phibbs RH, Wakeley A, et al. Cost effects of surfactant therapy for neonatal respiratory distress syndrome. J Pediatr 1993; 123: 953–62
Tubman TRJ, Halliday HL, Normand C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. Br Med J 1990; 301: 842–5
Bloom BT. Surfactant prophylaxis increases costs at more than 30 weeks. Pediatr Res 1994; 35: 217A
Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993; 123: 757–66
Rollins M, Jenkins J, Tubman R, et al. Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med 1993; 21: 341–7
Sehgal SS, Ewing CK, Richards T, et al. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Nat Med Assoc 1994; 86: 46–52
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: G. Bevilacqua, Institute of Child Health and Neonatal Medicine, University of Parma, Parma, Italy; C. Bose, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; P. Colditz, Perinatal Research Centre, Royal Women’s Hospital, Brisbane, Queensland, Australia; H. Egberts, Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, The Netherlands; T. Fujiwara, Department of Paediatrics, Iwate Medical University, Morioka, Japan; H. Halliday, Department of Neonatology, Royal Maternity Hospital, Belfast, Northern Ireland; M. Hallman, Division of Neonatology, University of California, Irvine, California, USA; T. Kobayashi, Department of Anaesthesiology, Kanazawa University, Kanazawa, Japan; B. Robertson, Department of Pathology, Karolinska Hospital, Stockholm, Sweden; O.D. Saugstad, Department of Pediatric Research, Rikshospitalet, Oslo, Norway; R.F. Soll, Department of Pediatrics, The University of Vermont, Burlington, Vermont, USA; Ch. P. Speer, Department of Pediatrics, University of Tübingen, Tübingen, Germany; R. Tubman, Neonatal Intensive Care Unit, Royal Maternity Hospital, Belfast, Northern Ireland; H. Walti, Service de Médecine Néonatale, Hôpital Port-Royal, Paris, France.
An erratum to this article is available at http://dx.doi.org/10.1007/BF03259145.
Rights and permissions
About this article
Cite this article
Wiseman, L.R., Bryson, H.M. Porcine-Derived Lung Surfactant. Drugs 48, 386–403 (1994). https://doi.org/10.2165/00003495-199448030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199448030-00006